3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents

Michael Maeng, Hans-Henrik Tilsted, Lisette Okkels Jensen, Anne Kaltoft, Henning Kelbæk, Ulrik Abildgaard, Anton Boel Villadsen, Lars Romer Krusell, Jan Ravkilde, Knud Nørregaard Hansen, Evald Høj Christiansen, Jens Aarøe, Jan Skov Jensen, Steen Dalby Kristensen, Hans Erik Bøtker, Morten Madsen, Per Thayssen, Henrik Toft Sørensen, Leif Thuesen, Jens Flensted Lassen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

38 Citationer (Scopus)

Abstract

This study sought to examine the 3-year clinical outcomes in patients treated with the Endeavor (Medtronic, Santa Rosa, California) zotarolimus-eluting stent (ZES) or the Cypher (Cordis, Johnson & Johnson, Warren, New Jersey) sirolimus-eluting stent (SES) in routine clinical practice.
OriginalsprogEngelsk
TidsskriftJACC. Cardiovascular interventions
Vol/bind5
Sider (fra-til)812-8
Antal sider7
ISSN1936-8798
DOI
StatusUdgivet - 2012
Udgivet eksterntJa

Fingeraftryk

Dyk ned i forskningsemnerne om '3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents'. Sammen danner de et unikt fingeraftryk.

Citationsformater